OncoMatch/Clinical Trials/NCT07003295
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
Is NCT07003295 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Glofitamab and Obinutuzumab for recurrent mantle cell lymphoma.
Treatment: Glofitamab · Obinutuzumab — This phase II trial tests the safety and side effects of glofitamab and obinutuzumab and how well they work in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory) after receiving CD19-directed chimeric antigen receptor (CAR) T-cell therapy. CAR T-cell therapy is a form of immunotherapy where the immune system cell, T-cell, is changed to attack cancer cells. Glofitamab is a bispecific antibody that can bind to two different antigens at the same time. Glofitamab binds to CD3, a protein found on T cells (a type of white blood cell), and CD20 a protein found on B cells (another type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. Obinutuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Giving glofitamab and obinutuzumab may be safe, tolerable, and/or effective in treating patients with relapsed or refractory mantle cell lymphoma after receiving CD19-directed CAR T-cell therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: CAR-T cell therapy — anti-CD19
previously treated with an anti-CD19 CAR T-cell therapy
Must have received: BTK inhibitor
failed or been intolerant to Bruton's tyrosine kinase (BTK) inhibition
Cannot have received: bispecific antibody targeting both CD20 and CD3 (glofitamab)
prior treatment with glofitamab or other bispecific antibodies targeting both CD20 and CD3
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1,000/mcL; Platelets ≥ 50,000/mcL
Kidney function
Creatinine ≤ 1.5 x institutional ULN OR GFR ≥ 60 mL/min/1.73 m^2
Liver function
Total bilirubin ≤ 1.5 x institutional ULN or ≤ 3 x institutional ULN if the patient has Gilbert syndrome; AST/ALT ≤ 3 x institutional ULN
Absolute neutrophil count ≥ 1,000/mcL; Platelets ≥ 50,000/mcL; Total bilirubin ≤ 1.5 x institutional ULN or ≤ 3 x institutional ULN if the patient has Gilbert syndrome; AST/ALT ≤ 3 x institutional ULN; Creatinine ≤ 1.5 x institutional ULN OR GFR ≥ 60 mL/min/1.73 m^2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- JHU Sidney Kimmel Comprehensive Cancer Center LAO · Baltimore, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify